ferric derisomaltose + ferumoxytol

**Ferric derisomaltose + ferumoxytol** is a hypothetical combination of two intravenous iron replacement products used to treat iron deficiency anemia (IDA) in adults intolerant to or unresponsive to oral iron, or with non-hemodialysis-dependent chronic kidney disease (CKD). Ferric derisomaltose (e.g., Monoferric) features a short linear carbohydrate matrix of linked glucose units that binds elemental iron, enabling rapid single-dose infusions up to 1000 mg over 20 minutes with low risk of labile iron release.[1][5][7] Ferumoxytol (e.g., Feraheme) is a superparamagnetic iron oxide coated with a polyglucose sorbitol carboxymethylether shell, taken up by reticuloendothelial system macrophages for iron utilization in erythropoiesis, administered as two 510 mg doses over 1 minute each.[1][2][6] Both formulations replenish iron stores for hemoglobin synthesis without oral iron limitations, though no approved or studied combination exists; ferric derisomaltose shows marginally higher hypophosphatemia risk than ferumoxytol in comparative trials.[1][4]